|
humans |
48 |
|
medical sciences |
36 |
|
adult |
33 |
|
female |
33 |
|
male |
33 |
|
middle aged |
30 |
|
covid-19 |
26 |
|
sars-cov-2 |
24 |
|
gastroenterology |
22 |
|
epidemiology |
21 |
|
colonoscopy |
18 |
|
adolescent |
17 |
|
aspirin |
16 |
|
atrial fibrillation |
16 |
|
sars-cov |
16 |
|
colorectal cancer |
15 |
|
cross-sectional studies |
15 |
|
hong kong |
15 |
|
aged |
14 |
|
body mass index |
14 |
|
child |
14 |
|
complications |
14 |
|
coronavirus infection |
14 |
|
health outcomes |
14 |
|
immune activation |
14 |
|
intestine |
14 |
|
replication |
14 |
|
chinese |
13 |
|
cohort studies |
13 |
|
helicobacter pylori |
13 |
|
survival analysis |
13 |
|
body height |
12 |
|
elderly |
12 |
|
gastrointestinal bleeding |
12 |
|
hepatocellular carcinoma |
12 |
|
chemoprevention |
11 |
|
covid-19 vaccine |
11 |
|
gastric cancer |
11 |
|
inflammatory bowel disease |
11 |
|
advanced hcc |
10 |
|
advanced hepatocellular carcinoma |
10 |
|
autoimmune disorders |
10 |
|
child, preschool |
10 |
|
china |
10 |
|
double-blind method |
10 |
|
gastrointestinal haemorrhage |
10 |
|
metformin |
10 |
|
reference values |
10 |
|
sorafenib |
10 |
|
time in therapeutic range |
10 |
|
hepatitis |
9 |
|
prevalence |
9 |
|
adiponectin |
8 |
|
adiponectin - blood |
8 |
|
adverse events |
8 |
|
antibiotics |
8 |
|
carcinoma, hepatocellular - mortality - therapy |
8 |
|
chemoembolization, therapeutic - adverse effects - mortality |
8 |
|
child-pugh a |
8 |
|
child-pugh b |
8 |
|
cytology and histology |
8 |
|
enzyme-linked immunosorbent assay |
8 |
|
hong kong - epidemiology |
8 |
|
incidence |
8 |
|
infusions, intra-arterial |
8 |
|
liver neoplasms - mortality - therapy |
8 |
|
magnetic resonance imaging |
8 |
|
oncology medical sciences |
8 |
|
radiology and nuclear medicine pharmacy and pharmacology biology |
8 |
|
transarterial chemoembolization |
8 |
|
adenocarcinoma |
7 |
|
alkaline phosphatase |
7 |
|
asian continental ancestry group |
7 |
|
biliary |
7 |
|
biomarker |
7 |
|
body composition - physiology |
7 |
|
cholangiogram |
7 |
|
cohort study |
7 |
|
colon cancer |
7 |
|
crc |
7 |
|
down-regulation - physiology |
7 |
|
immortal time bias |
7 |
|
interval cancer |
7 |
|
intra-abdominal fat - physiopathology |
7 |
|
ketamine |
7 |
|
longitudinal studies |
7 |
|
magnetic resonance cholangiography |
7 |
|
mir-139-3p |
7 |
|
mir-622 |
7 |
|
mirna |
7 |
|
nonsteroidal anti-inflammatory drugs |
7 |
|
obstructive sleep apnea |
7 |
|
prospective studies |
7 |
|
proton pump inhibitors |
7 |
|
risk assessment |
7 |
|
risk factors |
7 |
|
sleep apnea, obstructive - diagnosis - physiopathology |
7 |
|
stroke |
7 |
|
subcutaneous fat, abdominal - physiopathology |
7 |
|
substance abuse |
7 |
|
sympathetic activity |
7 |
|
sympathetic nervous system - physiopathology |
7 |
|
tumor markers, biological - analysis |
7 |
|
type 2 diabetes mellitus |
7 |
|
antipsychotic agents - therapeutic use |
6 |
|
bevacizumab |
6 |
|
blood pressure |
6 |
|
body weight |
6 |
|
chemotherapy |
6 |
|
clinical trials |
6 |
|
colon neoplasms |
6 |
|
curative colectomy |
6 |
|
dabigatran |
6 |
|
dibenzothiazepines - therapeutic use |
6 |
|
erlotinib |
6 |
|
follow up |
6 |
|
gastrointestinal tumours |
6 |
|
hospitalization |
6 |
|
infant |
6 |
|
meta-analysis |
6 |
|
point mutation - genetics |
6 |
|
preventive medicine |
6 |
|
primary care |
6 |
|
prognosis |
6 |
|
psychotic disorders - drug therapy |
6 |
|
recurrence |
6 |
|
rivaroxaban |
6 |
|
sorafenib-refractory |
6 |
|
stomach cancer |
6 |
|
time factors |
6 |
|
ulcerative colitis |
6 |
|
warfarin |
6 |
|
young adult |
6 |
|
aged, 80 and over |
5 |
|
alpha-fetoprotein |
5 |
|
angiotensin-converting enzyme inhibitors |
5 |
|
anticoagulant |
5 |
|
artificial intelligence |
5 |
|
bacteria |
5 |
|
bleeding |
5 |
|
cancer incidence |
5 |
|
cancer risk |
5 |
|
carcinoma, hepatocellular - diagnosis - mortality |
5 |
|
carrier proteins - genetics |
5 |
|
case-control studies |
5 |
|
cholesterol - blood |
5 |
|
clopidogrel |
5 |
|
cohort analysis |
5 |
|
colonic neoplasms |
5 |
|
comorbidity |
5 |
|
crohn's disease |
5 |
|
dyspepsia |
5 |
|
endoscopic retrograde cholangiopancreatography |
5 |
|
endoscopic sphicterotomy |
5 |
|
esomeprazole |
5 |
|
fecal-to-oral transmission |
5 |
|
forced expiratory volume - physiology |
5 |
|
gastroesophageal reflux |
5 |
|
gastrointestinal hemorrhage |
5 |
|
hippo signaling |
5 |
|
infant, newborn |
5 |
|
intestinal metaplasia |
5 |
|
length |
5 |
|
liver neoplasms - diagnosis - mortality |
5 |
|
methylation |
5 |
|
noncardiac chest pain |
5 |
|
non–vitamin k antagonist oral anticoagulants |
5 |
|
nsaid |
5 |
|
nuclear proteins - analysis |
5 |
|
outcome |
5 |
|
overall survival |
5 |
|
papillotomy |
5 |
|
pilot projects |
5 |
|
post‐colonoscopy colorectal cancer |
5 |
|
prediction model |
5 |
|
prisma |
5 |
|
prognostic marker |
5 |
|
propensity score |
5 |
|
quality of life |
5 |
|
questionnaires |
5 |
|
readmission |
5 |
|
real‐life |
5 |
|
renin |
5 |
|
respiratory diseases |
5 |
|
roc curve |
5 |
|
sars |
5 |
|
severity of illness index |
5 |
|
surrogate |
5 |
|
tace |
5 |
|
transcription factors - analysis |
5 |
|
treatment outcome |
5 |
|
tumor recurrence |
5 |
|
viral persistence |
5 |
|
yes-associated protein |
5 |
|
13c-urea breath test |
4 |
|
adverse outcome |
4 |
|
age distribution |
4 |
|
ageaged |
4 |
|
aging |
4 |
|
albuminuria - physiopathology |
4 |
|
antibodies, bacterial - blood |
4 |
|
antiplatelet |
4 |
|
antiplatelet drugs |
4 |
|
anxiety - psychology |
4 |
|
audiovisual aids |
4 |
|
beta-thalassemia - physiopathology |
4 |
|
bioinformatics |
4 |
|
biological markers - blood |
4 |
|
bmi |
4 |
|
breathing exercises |
4 |
|
calcium channel blockers |
4 |
|
cardiology - education |
4 |
|
cardiovascular diseases - metabolism - physiopathology |
4 |
|
catch-up growth |
4 |
|
chi-square distribution |
4 |
|
child development |
4 |
|
children |
4 |
|
china - epidemiology |
4 |
|
china - ethnology |
4 |
|
circadian rhythm |
4 |
|
codon - genetics |
4 |
|
colonic adenoma. |
4 |
|
colonic polyp |
4 |
|
colorectal neoplasms |
4 |
|
colorectal polyp |
4 |
|
comprehension |
4 |
|
continuous positive airway pressure |
4 |
|
crc patients |
4 |
|
depression - psychology |
4 |
|
diagnostic biomarker |
4 |
|
drug use |
4 |
|
education, medical, undergraduate |
4 |
|
educational status |
4 |
|
endocuff |
4 |
|
exercise |
4 |
|
exercise therapy |
4 |
|
experimental design |
4 |
|
gastric adenocarcinoma |
4 |
|
growth - physiology |
4 |
|
growth curve |
4 |
|
h pylori |
4 |
|
health economics |
4 |
|
health knowledge, attitudes, practice |
4 |
|
health status |
4 |
|
health surveys |
4 |
|
heart rate |
4 |
|
helicobacter pylori - immunology - isolation & purification |
4 |
|
helicobacter pylori - treatment |
4 |
|
helicobacterpylori |
4 |
|
hepatitis b |
4 |
|
hpv vaccine |
4 |
|
hpv vaccine perception |
4 |
|
hpv vaccine questionnaire |
4 |
|
hpv vaccine survey |
4 |
|
human papillomavirus |
4 |
|
hypertension - physiopathology - psychology - therapy - urine |
4 |
|
insulin - metabolism |
4 |
|
insulin sensitivity |
4 |
|
karyotype |
4 |
|
latency interval |
4 |
|
lupus erythematosus, systemic - epidemiology - genetics |
4 |
|
malignancy |
4 |
|
mannose-binding lectins |
4 |
|
metagenomics |
4 |
|
microbiome |
4 |
|
micrornas - physiology |
4 |
|
mortality |
4 |
|
nafld |
4 |
|
nasal continuous positive airway pressure |
4 |
|
next generation sequencing |
4 |
|
nf-kappa b - physiology |
4 |
|
obstructive sleep apnoea |
4 |
|
oral anticoagulant |
4 |
|
oxygen - metabolism |
4 |
|
papillomaviridae - immunology |
4 |
|
papillomavirus infections - prevention & control - virology |
4 |
|
papillomavirus vaccines |
4 |
|
patient simulation |
4 |
|
peptic ulcer |
4 |
|
pharmacoepidemiology |
4 |
|
ppi |
4 |
|
prevention |
4 |
|
psychiatric status rating scales |
4 |
|
puberty, delayed |
4 |
|
qigong |
4 |
|
randomised controlled trial |
4 |
|
receptors, prostaglandin e, ep2 subtype - physiology |
4 |
|
receptors, prostaglandin e, ep4 subtype - physiology |
4 |
|
rectal cancer |
4 |
|
regression analysis |
4 |
|
renin - blood |
4 |
|
retrospective studies |
4 |
|
serum microrna (mirna) |
4 |
|
sex distribution |
4 |
|
shock - metabolism - physiopathology |
4 |
|
sleep apnea, obstructive - metabolism - therapy |
4 |
|
stomach |
4 |
|
stomach neoplasms - pathology |
4 |
|
students, medical |
4 |
|
surgery |
4 |
|
teaching - methods |
4 |
|
thinness |
4 |
|
thiopurine |
4 |
|
thiopurines |
4 |
|
time trend |
4 |
|
turner's syndrome |
4 |
|
uterine cervical neoplasms - prevention & control - virology |
4 |
|
vaccine |
4 |
|
weight |
4 |
|
3-month overall survival |
3 |
|
5-ht3 receptor antagonist |
3 |
|
adenocarcinoma - metabolism |
3 |
|
advanced liver cancer prognostic system |
3 |
|
age |
3 |
|
age factors |
3 |
|
analgesia |
3 |
|
anti-ulcer agents - therapeutic use |
3 |
|
antiemetic |
3 |
|
antineoplastic combined chemotherapy protocols - adverse effects - therapeutic use |
3 |
|
area under curve |
3 |
|
artificial ventilation |
3 |
|
bioimpedance |
3 |
|
bismuth - therapeutic use |
3 |
|
bone density - physiology |
3 |
|
bone mass density |
3 |
|
bronchiectasis - immunology - microbiology |
3 |
|
bungarotoxins - pharmacology |
3 |
|
c-reactive protein |
3 |
|
c-reactive protein - metabolism |
3 |
|
cancer |
3 |
|
carboplatin |
3 |
|
carcinogens - toxicity |
3 |
|
carrier proteins - blood |
3 |
|
caucasian |
3 |
|
cell line, tumor |
3 |
|
cell proliferation - drug effects |
3 |
|
cerebrovascular accident |
3 |
|
chemicals and cas registry numbers |
3 |
|
childhood |
3 |
|
childhood diabetes |
3 |
|
chronic obstructive pulmonary disease |
3 |
|
clinical trials. |
3 |
|
coronavirus |
3 |
|
covid-19 infection |
3 |
|
cox-2 |
3 |
|
cyclin d1 - metabolism |
3 |
|
cyclooxygenase 2 - drug effects - metabolism |
3 |
|
data collection |
3 |
|
development |
3 |
|
dexamethasone |
3 |
|
diagnosis |
3 |
|
dinoprostone - metabolism |
3 |
|
direct thrombin inhibitor |
3 |
|
disease outbreaks |
3 |
|
disease-free survival |
3 |
|
dose-response relationship, drug |
3 |
|
drug side effect |
3 |
|
drug therapy, combination - therapeutic use |
3 |
|
drugs, chinese herbal - adverse effects - therapeutic use |
3 |
|
dual-energy x-ray absorptiometry |
3 |
|
dyspepsia - microbiology |
3 |
|
electric impedance |
3 |
|
european continental ancestry group |
3 |
|
factor xa inhibitor |
3 |
|
fetal blood - chemistry |
3 |
|
follow-up studies |
3 |
|
forced expiratory volume |
3 |
|
functional residual capacity |
3 |
|
gastric carcinoma |
3 |
|
gastric dysplasia |
3 |
|
gastroscopy |
3 |
|
gene expression regulation - drug effects |
3 |
|
great britain - epidemiology |
3 |
|
growth |
3 |
|
h2ra |
3 |
|
healthcare dataset |
3 |
|
height |
3 |
|
helicobacter infections - complications |
3 |
|
helicobacter infections - diagnosis - immunology |
3 |
|
helicobacter infections - drug therapy |
3 |
|
hospitalization - statistics & numerical data |
3 |
|
human growth hormone - blood |
3 |
|
immune function |
3 |
|
infancy |
3 |
|
infant, newborn - physiology |
3 |
|
infection |
3 |
|
inflammation |
3 |
|
insulin-like growth factor binding protein 3 - blood |
3 |
|
insulin-like growth factor i - metabolism |
3 |
|
interleukin-6 |
3 |
|
interleukin-8 |
3 |
|
intrauterine growth retardation |
3 |
|
lung disease burden |
3 |
|
lung function |
3 |
|
lung volume measurements |
3 |
|
lymph-node metastasis |
3 |
|
magnifying endoscopy |
3 |
|
mannose-binding protein |
3 |
|
maximal expiratory flow rate |
3 |
|
metoclopramide |
3 |
|
monotherapy |
3 |
|
mutations |
3 |
|
nchs |
3 |
|
neoplasm staging |
3 |
|
nicotine |
3 |
|
nicotine - toxicity |
3 |
|
nicotinic acetylcholine receptor |
3 |
|
nitrosamines - toxicity |
3 |
|
nnk |
3 |
|
nutritional status |
3 |
|
organ size |
3 |
|
osteoporosis |
3 |
|
osteoporosis - diagnosis - physiopathology |
3 |
|
ovarian cancer |
3 |
|
ovarian neoplasms - drug therapy - immunology |
3 |
|
p38 mitogen-activated protein kinases - drug effects - metabolism |
3 |
|
parecoxib |
3 |
|
plethysmography |
3 |
|
polymerase chain reaction - methods |
3 |
|
postmenopause - physiology |
3 |
|
postnatal growth |
3 |
|
prematurity |
3 |
|
preterm infants |
3 |
|
prognostic score system |
3 |
|
propranolol - pharmacology |
3 |
|
proton pumps - antagonists & inhibitors |
3 |
|
pulmonary disease, chronic obstructive - blood - physiopathology |
3 |
|
ranitidine - analogs & derivatives - therapeutic use |
3 |
|
receptors, adrenergic, beta - drug effects - metabolism |
3 |
|
receptors, nicotinic - drug effects - metabolism |
3 |
|
research design |
3 |
|
residual volume |
3 |
|
respiratory tract diseases - epidemiology - mortality |
3 |
|
sensitivity and specificity |
3 |
|
sex factors |
3 |
|
signal transduction - drug effects |
3 |
|
smoking - blood |
3 |
|
spirometry |
3 |
|
staging |
3 |
|
stomach neoplasms - metabolism |
3 |
|
surgical injury |
3 |
|
total lung capacity |
3 |
|
traditional chinese medicine |
3 |
|
vaccines |
3 |
|
vital capacity |
3 |
|
β-adrenergic receptor |
3 |
|
2-cl-ib-meca |
2 |
|
5-ht |
2 |
|
610.72 s93 |
2 |
|
abstracting, bibliographies, statistics statistics |
2 |
|
acne vulgaris - physiopathology |
2 |
|
adenoma - epidemiology |
2 |
|
adenosine a3 receptor |
2 |
|
administration, intranasal |
2 |
|
adverse outcomes |
2 |
|
aerospace medicine |
2 |
|
allergic thiniris |
2 |
|
allergy |
2 |
|
allied health personnel - standards |
2 |
|
analysis of variance |
2 |
|
animals |
2 |
|
animals, newborn |
2 |
|
anti-bacterial agents |
2 |
|
anti-inflammatory agents, non-steroidal - administration & dosage - pharmacology |
2 |
|
anti-ulcer agents - diagnostic use - therapeutic use |
2 |
|
antibiotic |
2 |
|
antibodies, viral - blood |
2 |
|
anticarcinogenic agents - administration & dosage - pharmacology |
2 |
|
apixaban |
2 |
|
apoptosis - physiology |
2 |
|
aryl hydrocarbon receptor |
2 |
|
asthma |
2 |
|
asthma - epidemiology |
2 |
|
axilla |
2 |
|
azathioprine |
2 |
|
balloon dilation |
2 |
|
birth weight - physiology |
2 |
|
blood coagulation |
2 |
|
blood pressure - physiology |
2 |
|
breast - growth & development |
2 |
|
c-fos |
2 |
|
capsule endoscopy |
2 |
|
carcinoma |
2 |
|
carcinoma, squamous cell - mortality - pathology - surgery - therapy |
2 |
|
cardia |
2 |
|
catch-down growth posttreatment |
2 |
|
chemopreventive agents |
2 |
|
chest pain - etiology |
2 |
|
cholangitis - pathology |
2 |
|
clinical trials -- standards -- china |
2 |
|
colon - innervation - metabolism - physiopathology |
2 |
|
colonic polyps - epidemiology |
2 |
|
colorectal neoplasms - epidemiology |
2 |
|
congenital heart disease |
2 |
|
consensus |
2 |
|
cytomegalovirus (cmv) |
2 |
|
cytomegalovirus - genetics - immunology |
2 |
|
developing country |
2 |
|
dexmedetomidine - administration and dosage |
2 |
|
diabetes mellitus |
2 |
|
diagnostic techniques, digestive system |
2 |
|
diarrhea - pathology - virology |
2 |
|
disease models, animal |
2 |
|
dissection |
2 |
|
dna, viral - blood |
2 |
|
dnaemia |
2 |
|
dtl/ramp |
2 |
|
dyspepsia - drug therapy |
2 |
|
eczema |
2 |
|
eczema - epidemiology |
2 |
|
edoxaban |
2 |
|
elderly-onset |
2 |
|
endoscopy |
2 |
|
endoscopy, gastrointestinal - methods |
2 |
|
enteritis - pathology - virology |
2 |
|
enterochromaffin-like cells |
2 |
|
ethnic contrast |
2 |
|
ethnicity |
2 |
|
factor v |
2 |
|
factor v - genetics - metabolism |
2 |
|
fbln1 |
2 |
|
feces - virology |
2 |
|
fetal growth |
2 |
|
final height |
2 |
|
foetal growth retardation |
2 |
|
follow-up |
2 |
|
gastric neoplasia |
2 |
|
gastrin |
2 |
|
gastroesophageal reflux - complications - diagnosis - drug therapy |
2 |
|
gene expression |
2 |
|
gestational age |
2 |
|
groin |
2 |
|
growth and development |
2 |
|
growth determination |
2 |
|
growth dynamics |
2 |
|
growth evaluation |
2 |
|
growth faltering |
2 |
|
growth hormone |
2 |
|
growth pattern |
2 |
|
growth phase |
2 |
|
gut microbiota |
2 |
|
h pylori eradication |
2 |
|
h. pylori |
2 |
|
hair - growth & development |
2 |
|
herpesviridae infections - blood - immunology - virology |
2 |
|
herpesvirus 6, human - genetics - immunology |
2 |
|
herpesvirus 7, human - genetics - immunology |
2 |
|
heterozygote |
2 |
|
human herpesvirus 6 (hhv6) and 7 (hhv7) |
2 |
|
hypnotics and sedatives - administration and dosage |
2 |
|
ibd |
2 |
|
immobilization |
2 |
|
immobilization - physiology |
2 |
|
immunohistochemistry |
2 |
|
infant mortality |
2 |
|
infantile diarrhoea |
2 |
|
infants |
2 |
|
inflammatory bowel diseases |
2 |
|
intensive care units |
2 |
|
irritable bowel syndrome - diagnosis - therapy |
2 |
|
irritable bowel syndrome - metabolism - physiopathology |
2 |
|
isaac |
2 |
|
kaplan-meier estimate |
2 |
|
kidney transplantation - adverse effects |
2 |
|
knemometry |
2 |
|
l2dtl |
2 |
|
leukocytes, mononuclear - immunology - virology |
2 |
|
linear growth |
2 |
|
longitudinal follow-up |
2 |
|
longitudinal study |
2 |
|
low dose |
2 |
|
lower leg length |
2 |
|
lung - physiology |
2 |
|
maternal deprivation |
2 |
|
maternal smoking |
2 |
|
measuring error |
2 |
|
medicine, chinese traditional - standards |
2 |
|
menarche - physiology |
2 |
|
monitoring, physiologic - methods |
2 |
|
motor development |
2 |
|
natural history |
2 |
|
neck |
2 |
|
neck dissection - methods |
2 |
|
neonatal maternal separation |
2 |
|
neonatal mortality |
2 |
|
neoplasm recurrence, local - mortality - pathology |
2 |
|
nf-kappa b |
2 |
|
non-gh deficient |
2 |
|
non-ulcer dyspepsia |
2 |
|
novel anticoagulants |
2 |
|
nuclear proteins - genetics - metabolism |
2 |
|
obesity |
2 |
|
observation - methods |
2 |
|
observer variation |
2 |
|
odds ratio |
2 |
|
oncogene |
2 |
|
p21 |
2 |
|
p53 |
2 |
|
pain threshold |
2 |
|
pakistan |
2 |
|
patient selection |
2 |
|
peptic ulcer - microbiology |
2 |
|
peptic ulcer disease |
2 |
|
peripheral blood leukocytes |
2 |
|
physical examination |
2 |
|
polymerase chain reaction (pcr) |
2 |
|
post-campaign |
2 |
|
postneonatal deaths |
2 |
|
postneonatal mortality |
2 |
|
posture |
2 |
|
posture - physiology |
2 |
|
ppis |
2 |
|
prediction |
2 |
|
pregnancy |
2 |
|
premedication - methods |
2 |
|
prenatal growth |
2 |
|
preschool |
2 |
|
pressure |
2 |
|
primary teeth emergence |
2 |
|
probability |
2 |
|
proportionality |
2 |
|
proto-oncogene proteins c-fos - metabolism |
2 |
|
proton pump inhibition |
2 |
|
proximal colonic cancer |
2 |
|
puberty - physiology |
2 |
|
race |
2 |
|
randomized |
2 |
|
randomized controlled trials as topic |
2 |
|
raphe nuclei - metabolism |
2 |
|
rats |
2 |
|
rats, sprague-dawley |
2 |
|
receptors, serotonin, 5-ht3 - genetics - metabolism |
2 |
|
references (31) view in table layout |
2 |
|
reflex - physiology |
2 |
|
renal allograft |
2 |
|
rhinitis |
2 |
|
rhinitis, allergic, perennial - epidemiology |
2 |
|
rna, viral - analysis |
2 |
|
sars virus - genetics - isolation & purification |
2 |
|
seasonality |
2 |
|
serological responses |
2 |
|
serotonin |
2 |
|
serotonin - metabolism |
2 |
|
serotonin plasma membrane transport proteins - genetics - metabolism |
2 |
|
serrated lesion |
2 |
|
sessile serrated adenoma/polyp |
2 |
|
severe acute respiratory syndrome - complications - pathology |
2 |
|
severe acute respiratory syndrome - epidemiology - prevention & control - transmission |
2 |
|
sex characteristics |
2 |
|
short for gestational age |
2 |
|
short stature |
2 |
|
short term |
2 |
|
shortness |
2 |
|
sids |
2 |
|
size at birth |
2 |
|
small for gestational age |
2 |
|
socioeconomic factors |
2 |
|
soft tissue |
2 |
|
spinal cord - metabolism |
2 |
|
steroid-dependent ulcerative colitis |
2 |
|
stomach neoplasms - epidemiology - microbiology - prevention & control |
2 |
|
stomach neoplasms - genetics - metabolism |
2 |
|
stress, psychological - metabolism - physiopathology |
2 |
|
surveillance |
2 |
|
sweden |
2 |
|
systematic reviews as topic |
2 |
|
target height |
2 |
|
temperature |
2 |
|
tongue |
2 |
|
tongue neoplasms - mortality - pathology - surgery - therapy |
2 |
|
tooth, deciduous - growth & development |
2 |
|
transplantation, homologous |
2 |
|
transportation - statistics & numerical data |
2 |
|
travel |
2 |
|
treatment |
2 |
|
triple therapy |
2 |
|
tumour suppressor gene |
2 |
|
tumourigenesis |
2 |
|
twins |
2 |
|
urban population |
2 |
|
urbanization |
2 |
|
venous thrombosis |
2 |
|
venous thrombosis - epidemiology |
2 |
|
venous thrombosis - genetics |
2 |
|
visceral hyperalgesia |
2 |
|
vital capacity - physiology |
2 |
|
world health |
2 |
|
2-pyridinylmethylsulfinylbenzimidazoles - administration & dosage - therapeutic use |
1 |
|
3' untranslated regions - genetics |
1 |
|
3′-untranslated region |
1 |
|
5- aminosalicylic acid |
1 |
|
570.7205 k18 |
1 |
|
abdominal pain - etiology |
1 |
|
abo blood-group system - genetics |
1 |
|
acid suppression |
1 |
|
actins - genetics - metabolism |
1 |
|
acute diarrhoea |
1 |
|
adalimumab |
1 |
|
adaptor proteins, signal transducing |
1 |
|
adenocarcinoma - blood - diagnosis - genetics |
1 |
|
adenocarcinoma - blood - metabolism - pathology |
1 |
|
adenocarcinoma - chemistry - metabolism - pathology |
1 |
|
adenocarcinoma - drug therapy - pathology |
1 |
|
adenocarcinoma - enzymology - genetics - pathology - surgery |
1 |
|
adenocarcinoma - enzymology - microbiology - pathology |
1 |
|
adenocarcinoma - genetics |
1 |
|
adenocarcinoma - genetics - metabolism |
1 |
|
adenocarcinoma - genetics - microbiology |
1 |
|
adenocarcinoma - microbiology |
1 |
|
adenocarcinoma - pathology - prevention & control |
1 |
|
adenoma |
1 |
|
adenoma - diagnosis |
1 |
|
adenoma - epidemiology - pathology |
1 |
|
adenoma - genetics - pathology |
1 |
|
adenoma detection rate |
1 |
|
adenosine triphosphatases |
1 |
|
adhesins, bacterial |
1 |
|
adiposity rebound |
1 |
|
adolescence |
1 |
|
adoption |
1 |
|
adoption - ethnology |
1 |
|
adriamycin |
1 |
|
adult overweight |
1 |
|
age at phv |
1 |
|
aging - physiology |
1 |
|
agranulocytosis |
1 |
|
agranulocytosis - chemically induced |
1 |
|
agriculture |
1 |
|
air |
1 |
|
alanine transaminase - blood |
1 |
|
alcohol drinking |
1 |
|
allergens |
1 |
|
amino acid sequence |
1 |
|
amino acid substitution |
1 |
|
amoxicillin - administration & dosage - therapeutic use |
1 |
|
amoxicillin - therapeutic use |
1 |
|
ampicillin - administration & dosage |
1 |
|
anabolic agents - therapeutic use |
1 |
|
anemia, iron-deficiency - etiology |
1 |
|
angiodysplasia - diagnosis |
1 |
|
angiogenesis |
1 |
|
angiogenesis inhibitors - pharmacology |
1 |
|
angiography |
1 |
|
angiopoietin |
1 |
|
angiopoietin-1 - genetics |
1 |
|
annexin a5 - pharmacology |
1 |
|
antacids - therapeutic use |
1 |
|
anti-bacterial agents - administration & dosage |
1 |
|
anti-bacterial agents - administration & dosage - therapeutic use |
1 |
|
anti-bacterial agents - pharmacology |
1 |
|
anti-bacterial agents - pharmacology - therapeutic use |
1 |
|
anti-bacterial agents - therapeutic use |
1 |
|
anti-hiv agents - therapeutic use |
1 |
|
anti-infective agents - administration & dosage |
1 |
|
anti-inflammatory agents |
1 |
|
anti-inflammatory agents, non-steroidal - administration & dosage - adverse effects - therapeutic use |
1 |
|
anti-inflammatory agents, non-steroidal - adverse effects |
1 |
|
anti-inflammatory agents, non-steroidal - adverse effects - therapeutic use |
1 |
|
anti-inflammatory agents, non-steroidal - pharmacology - therapeutic use |
1 |
|
anti-inflammatory agents, non-steroidal - therapeutic use |
1 |
|
anti-ulcer agents - administration & dosage |
1 |
|
anti-ulcer agents - administration & dosage - therapeutic use |
1 |
|
anti-ulcer agents - adverse effects - therapeutic use |
1 |
|
antibiotics, antineoplastic - pharmacology |
1 |
|
antibodies, antineutrophil cytoplasmic - analysis |
1 |
|
antibodies, bacterial - analysis |
1 |
|
antibodies, fungal - analysis |
1 |
|
antibodies, viral - diagnostic use |
1 |
|
antigens, bacterial |
1 |
|
antigens, bacterial - analysis |
1 |
|
antigens, bacterial - genetics |
1 |
|
antigens, bacterial - immunology |
1 |
|
antigens, cd34 - biosynthesis |
1 |
|
antigens, surface - genetics - metabolism |
1 |
|
antimetabolites, antineoplastic - pharmacology |
1 |
|
antineoplastic agents - administration & dosage |
1 |
|
antineoplastic agents - pharmacology |
1 |
|
antineoplastic agents - therapeutic use |
1 |
|
antiparasitic agents - therapeutic use |
1 |
|
antisense |
1 |
|
antiviral agents - therapeutic use |
1 |
|
apgar score |
1 |
|
apoptosis |
1 |
|
apoptosis - drug effects |
1 |
|
apoptosis - drug effects - genetics |
1 |
|
apoptosis regulatory proteins |
1 |
|
area under the curve |
1 |
|
arthritis - drug therapy |
1 |
|
asia - epidemiology |
1 |
|
asia - ethnology |
1 |
|
asia, southeastern - epidemiology |
1 |
|
asphyxia neonatorum - mortality |
1 |
|
aspirin - administration & dosage - adverse effects |
1 |
|
aspirin - adverse effects |
1 |
|
aspirin - adverse effects - therapeutic use |
1 |
|
atrophy |
1 |
|
au-rich element |
1 |
|
autoimmunity |
1 |
|
azacitidine |
1 |
|
azacitidine - pharmacology |
1 |
|
bacteraemia |
1 |
|
bacteremia - diagnosis - metabolism - microbiology |
1 |
|
bacteremia - drug therapy |
1 |
|
bacteremia - drug therapy - etiology - transmission |
1 |
|
bacterial proteins - genetics |
1 |
|
bacterial vaccines |
1 |
|
bacteriological techniques - statistics & numerical data |
1 |
|
base pair mismatch |
1 |
|
base pair mismatch - genetics |
1 |
|
base sequence |
1 |
|
bcl2 |
1 |
|
benn index |
1 |
|
benzamides - administration & dosage - pharmacology |
1 |
|
benzodiazepines |
1 |
|
beta catenin |
1 |
|
bilirubin |
1 |
|
biologics |
1 |
|
biopsy |
1 |
|
biopsy, needle |
1 |
|
biosimilar |
1 |
|
birth |
1 |
|
birth defects |
1 |
|
birth length |
1 |
|
birth register |
1 |
|
birth weight |
1 |
|
birthweight |
1 |
|
bismuth - administration & dosage |
1 |
|
bismuth - administration & dosage - therapeutic use |
1 |
|
bites, human |
1 |
|
bivalvia - microbiology |
1 |
|
blotting, southern |
1 |
|
blotting, western |
1 |
|
body height - genetics |
1 |
|
body height - physiology |
1 |
|
body mass index reference values |
1 |
|
box transformation |
1 |
|
breast feeding |
1 |
|
breastfeeding |
1 |
|
breath tests |
1 |
|
bromocriptine |
1 |
|
bromocriptine - therapeutic use |
1 |
|
buffers |
1 |
|
butanones - therapeutic use |
1 |
|
cadherins - biosynthesis - genetics - metabolism |
1 |
|
cadherins - genetics |
1 |
|
cadherins - genetics - metabolism |
1 |
|
cadherins - metabolism |
1 |
|
cadmium - pharmacology |
1 |
|
calcium-calmodulin-dependent protein kinases - genetics |
1 |
|
calcium-calmodulin-dependent protein kinases - metabolism |
1 |
|
caliciviridae infections - classification - epidemiology - genetics |
1 |
|
caliciviridae infections - epidemiology - transmission - virology |
1 |
|
caliciviridae infections - virology |
1 |
|
capsid |
1 |
|
capsule endoscopy - methods |
1 |
|
capsules |
1 |
|
carbon isotopes - diagnostic use |
1 |
|
carcinoma - enzymology |
1 |
|
carcinoma - epidemiology - pathology |
1 |
|
carcinoma - genetics |
1 |
|
carcinoma - genetics - pathology |
1 |
|
carcinoma, hepatocellular - blood supply - enzymology - virology |
1 |
|
carcinoma, hepatocellular - drug therapy - pathology |
1 |
|
carcinoma, hepatocellular - metabolism - pathology |
1 |
|
carcinoma, small cell |
1 |
|
cardiovascular diseases - prevention & control |
1 |
|
carrier proteins |
1 |
|
carrier proteins - biosynthesis - metabolism |
1 |
|
carrier proteins - genetics - metabolism |
1 |
|
case mortality |
1 |
|
caspase 3 |
1 |
|
caspases - metabolism |
1 |
|
catalase |
1 |
|
catalase - metabolism |
1 |
|
catatonia - diagnosis - drug therapy - psychology |
1 |
|
ccl4 |
1 |
|
cecum |
1 |
|
ceftazidime - administration & dosage |
1 |
|
celecoxib |
1 |
|
cell culture techniques |
1 |
|
cell culture techniques - methods |
1 |
|
cell cycle |
1 |
|
cell cycle proteins |
1 |
|
cell division |
1 |
|
cell division - drug effects |
1 |
|
cell kinetics |
1 |
|
cell line |
1 |
|
cell proliferation |
1 |
|
cell transformation, neoplastic |
1 |
|
cell transformation, neoplastic - genetics |
1 |
|
cell viability assay |
1 |
|
cells, cultured |
1 |
|
chemokines - metabolism |
1 |
|
chemoprevention - methods |
1 |
|
chemotaxis |
1 |
|
child care practices |
1 |
|
child development - physiology |
1 |
|
child growth |
1 |
|
childhood onset of growth |
1 |
|
cholangiopancreatography, endoscopic retrograde - methods |
1 |
|
choledocholithiasis - complications - diagnosis |
1 |
|
cholestasis, extrahepatic - diagnosis - etiology |
1 |
|
choline deficiency |
1 |
|
chromatin remodeling |
1 |
|
chromatography, high pressure liquid |
1 |
|
chromosomal proteins, non-histone - biosynthesis |
1 |
|
chronic hepatitis b |
1 |
|
chronic renal failure |
1 |
|
chronic ulcerative colitis |
1 |
|
cirrhosis |
1 |
|
cisplatin - therapeutic use |
1 |
|
clarithromycin |
1 |
|
clarithromycin - administration & dosage - therapeutic use |
1 |
|
clarithromycin - pharmacology |
1 |
|
clarithromycin - pharmacology - therapeutic use |
1 |
|
clarithromycin - therapeutic use |
1 |
|
clarithromycin-containing triple therapy |
1 |
|
clinical competence |
1 |
|
clinical outcomes |
1 |
|
clinical stool specimens |
1 |
|
clinical trials - methods |
1 |
|
clinical trials as topic |
1 |
|
clinical trials as topic - methods |
1 |
|
clinicopathologic features |
1 |
|
clobetasol - adverse effects |
1 |
|
clostridium difficile |
1 |
|
cloxacillin |
1 |
|
cloxacillin - adverse effects |
1 |
|
coagulability |
1 |
|
cochrane library |
1 |
|
colitis |
1 |
|
colitis, ulcerative |
1 |
|
colitis, ulcerative - complications - diagnosis - drug therapy - epidemiology - therapy |
1 |
|
colitis, ulcerative - complications - epidemiology - pathology - surgery |
1 |
|
colon - pathology |
1 |
|
colon cancer detection |
1 |
|
colonic neoplasms - diagnosis |
1 |
|
colonic polyps - diagnosis |
1 |
|
colonoscopes |
1 |
|
colonoscopy - adverse effects |
1 |
|
colonoscopy - methods |
1 |
|
colonoscopy - statistics & numerical data |
1 |
|
colorectal lesion |
1 |
|
colorectal neoplasms - complications - epidemiology - ethnology - pathology |
1 |
|
colorectal neoplasms - diagnosis |
1 |
|
colorectal neoplasms - diagnosis - enzymology |
1 |
|
colorectal neoplasms - diagnosis - ethnology |
1 |
|
colorectal neoplasms - epidemiology - mortality |
1 |
|
colorectal neoplasms - etiology |
1 |
|
colorectal neoplasms - genetics |
1 |
|
colorectal neoplasms - genetics - pathology |
1 |
|
colorectal neoplasms - pathology |
1 |
|
coloring agents |
1 |
|
combined modality therapy |
1 |
|
comet assay |
1 |
|
common bile duct |
1 |
|
community-based |
1 |
|
comparison |
1 |
|
confidence intervals |
1 |
|
congresses as topic |
1 |
|
connective tissue growth factor |
1 |
|
continuing |
1 |
|
cooking and eating utensils |
1 |
|
covid‐19 |
1 |
|
cpg islands |
1 |
|
crohn |
1 |
|
crohn disease |
1 |
|
crohn disease - classification - pathology - surgery |
1 |
|
crohn disease - complications - immunology |
1 |
|
culture |
1 |
|
culture media |
1 |
|
cyanoacrylates - diagnostic use |
1 |
|
cyclin d1 - analysis - biosynthesis |
1 |
|
cyclin d2 |
1 |
|
cyclin-dependent kinase inhibitor p15 |
1 |
|
cyclin-dependent kinase inhibitor p16 - metabolism |
1 |
|
cyclin-dependent kinase inhibitor p21 |
1 |
|
cyclin-dependent kinases - metabolism |
1 |
|
cyclins - biosynthesis |
1 |
|
cyclins - metabolism |
1 |
|
cyclo-oxygenase-2 |
1 |
|
cyclooxygenase 1 |
1 |
|
cyclooxygenase 2 |
1 |
|
cyclooxygenase 2 - analysis |
1 |
|
cyclooxygenase 2 - analysis - metabolism |
1 |
|
cyclooxygenase 2 - genetics |
1 |
|
cyclooxygenase 2 - genetics - metabolism |
1 |
|
cyclooxygenase 2 - genetics - metabolism - physiology |
1 |
|
cyclooxygenase 2 inhibitors |
1 |
|
cyclooxygenase 2 inhibitors - pharmacology |
1 |
|
cyclooxygenase 2 inhibitors - therapeutic use |
1 |
|
cyclooxygenase inhibitors - administration & dosage - therapeutic use |
1 |
|
cyclooxygenase inhibitors - adverse effects - therapeutic use |
1 |
|
cyclooxygenase inhibitors - pharmacology |
1 |
|
cyclooxygenase inhibitors - therapeutic use |
1 |
|
cyclooxygenase-2 |
1 |
|
cysteine endopeptidases - metabolism |
1 |
|
cysteine proteinase inhibitors - pharmacology |
1 |
|
cytokines - genetics |
1 |
|
cytokines - metabolism |
1 |
